Piramal Pharma Limited

NSE PPLPHARMA.NS

Piramal Pharma Limited Price to Book Ratio (P/B) on January 14, 2025: 3.71

Piramal Pharma Limited Price to Book Ratio (P/B) is 3.71 on January 14, 2025, a 36.87% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Piramal Pharma Limited 52-week high Price to Book Ratio (P/B) is 4.84 on November 06, 2024, which is 30.44% above the current Price to Book Ratio (P/B).
Piramal Pharma Limited 52-week low Price to Book Ratio (P/B) is 2.16 on April 01, 2024, which is -41.87% below the current Price to Book Ratio (P/B).
Piramal Pharma Limited average Price to Book Ratio (P/B) for the last 52 weeks is 3.10.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NSE: PPLPHARMA.NS

Piramal Pharma Limited

CEO	Mr. Peter Daniel DeYoung
IPO Date	Oct. 19, 2022
Location	India
Headquarters	507, Skyline Wealth Space
Employees	6,719
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Piramal Pharma Limited operates as a pharmaceutical company. It sells a portfolio of pharma products, as well as provides various pharma services, including injection, HPAPI, etc. The company was incorporated in 2020 and is based in Mumbai, India. Piramal Pharma Limited operates as a subsidiary of Piramal Enterprises Limited.

Key trends

Past 5 years